Certara (NASDAQ:CERT) Price Target Cut to $20.00

Certara (NASDAQ:CERT) had its target price cut by research analysts at KeyCorp from $23.00 to $20.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s price objective would suggest a potential upside of 31.75% from the company’s previous close.

A number of other equities analysts also recently issued reports on CERT. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Wednesday. Barclays dropped their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Seven investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Certara presently has an average rating of “Hold” and a consensus price target of $19.44.

Certara Stock Up 0.4 %

Certara stock opened at $15.18 on Thursday. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -38.92, a PEG ratio of 4.78 and a beta of 1.52. The stock has a fifty day simple moving average of $15.49 and a two-hundred day simple moving average of $16.67. Certara has a 12 month low of $11.81 and a 12 month high of $19.87. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The firm had revenue of $96.65 million during the quarter, compared to analysts’ expectations of $94.48 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. Equities analysts predict that Certara will post 0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

Institutional investors and hedge funds have recently bought and sold shares of the stock. Comerica Bank raised its holdings in Certara by 1.7% during the fourth quarter. Comerica Bank now owns 55,469 shares of the company’s stock valued at $976,000 after acquiring an additional 929 shares during the period. Russell Investments Group Ltd. raised its holdings in Certara by 1.6% during the first quarter. Russell Investments Group Ltd. now owns 77,753 shares of the company’s stock valued at $1,375,000 after acquiring an additional 1,191 shares during the period. Texas Permanent School Fund Corp raised its holdings in Certara by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 93,729 shares of the company’s stock valued at $1,676,000 after acquiring an additional 1,213 shares during the period. Pineridge Advisors LLC bought a new stake in Certara during the fourth quarter valued at about $28,000. Finally, Global Retirement Partners LLC raised its holdings in Certara by 5,306.3% during the first quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after acquiring an additional 1,698 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.